Which cancer drugs compete with Keytruda (pembrolizumab) across major indications?
Keytruda (pembrolizumab) is an anti-PD-1 immunotherapy used in multiple cancers. Its main competitors are other immune checkpoint inhibitors and a few combination immunotherapy regimens that target similar pathways:
- Other PD-1/PD-L1 checkpoint inhibitors: drugs in the same class that also block PD-1 or PD-L1 and are used in overlapping tumor types and lines of therapy.
- CTLA-4–based regimens: combinations that add CTLA-4 blockade (often alongside PD-1/PD-L1 inhibition) to improve responses in some indications.
- Competing non-checkpoint immunotherapies and combination therapies: in practice, oncologists may choose alternatives that combine immunotherapy with chemotherapy, targeted therapy, or other immuno-oncology approaches, depending on the cancer type and biomarker status.
What are the most direct brand-name competitors?
In the immune checkpoint inhibitor space, the most direct competitors to Keytruda are commonly the other widely used PD-1 and PD-L1 agents, including:
- Opdivo (nivolumab)
- Tecentriq (atezolizumab)
- Imfinzi (durvalumab)
- Bavencio (avelumab)
- Libtayo (cemiplimab)
- Imjudo (tremelimumab, CTLA-4) when used in regimens that compete for similar treatment settings
How does competition change by cancer type and biomarker (PD-L1, MSI-H/dMMR)?
Keytruda’s “main” competitor depends heavily on the tumor and the biomarker that guides eligibility:
- PD-L1–high settings: PD-1/PD-L1 inhibitors from other companies may be used head-to-head or sequentially.
- MSI-H/dMMR (mismatch repair–deficient) tumors: competitors that target the same biology through checkpoint blockade compete for first-line and subsequent use.
- Tumor-specific standards: for some cancers, a combination regimen may be preferred over single-agent PD-1 therapy, shifting which drugs are the closest alternatives.
Are targeted therapies and chemo-immunotherapy also competing with Keytruda?
Yes. Even when the competitor isn’t another PD-1/PD-L1 drug, oncologists often weigh Keytruda against:
- chemo-immunotherapy combinations
- targeted therapies matched to mutations (when available)
- other immunotherapy combinations
These options compete for use in the same lines of therapy and can affect Keytruda’s market share in specific indications.
Sources
I don’t have any provided source documents or links in this chat, so I can’t cite specific competitor lists from the requested materials. If you share the sources you want me to use (or paste a competitor page/table), I can extract the key competitors from that information and cite them precisely.